| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d0b5206aaaa7ccf76abe51849d5c0c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e7e29d2da031ded2efe73d7880e56ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 |
| filingDate |
1992-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86e1fa994528b6bea9bbf03b5fea894f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40cb6f84e3eaa2be19d61ae7afa2f5ab |
| publicationDate |
1994-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9413282-A1 |
| titleOfInvention |
Treatment of lymes disease and associated debilitating conditions |
| abstract |
The use of a psoralen compound in human patients who have Lymes disease is described. The psoralen compound is preferably administered in a dosage of 0.3 to 0.7 mg/kg and activated either in vitro or in vivo using eletromagnetic radiation of a prescribed activating wavelength. The activation of the psoralen compound in the presence of a blood fraction from a patient suffering from Lymes disease produces a composition which will stimulate an effective immune response to the Lymes disease on the part of the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8142763-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017155465-A1 |
| priorityDate |
1991-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |